Jan. 21, 2025
| Today’s news and insights for biopharma leaders
The startups are the fourth and fifth drugmakers to file for initial stock sales since late December — the most IPO activity in more than three months.
|
The rescinded Biden-era orders include actions to boost the Affordable Care Act exchanges, coordinate the government’s COVID-19 response and deploy artificial intelligence tools.
|
The clearance of Datroway comes months after the companies narrowed approval plans in lung cancer and opens up a market opportunity analysts estimate to be worth about $500 million annually.
|
What does 2025 hold for pharma? Find out the top drugs, companies and therapy areas for the year ahead.
|
Moderna has been testing an mRNA candidate for influenza viruses like the H5 and H7 strains that are seen as pandemic threats. Others, including GSK and Pfizer, are also at work on similar shots.
|
Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.
|
|
Explore how MIDD can address global health disparities by ensuring moxidectin is safely used in breastfeeding women.
|
|
From Our Library
Playbook
Custom content for WCG
|
Infographic
Custom content for WCG
|
Trendline
Supported by Premier Inc
|
Playbook
Custom content for Integrity Solutions
| | 
